These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34740274)

  • 1. Raloxifene in the Treatment of Osteoporosis in Postmenopausal Women with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
    Ma HY; Chen S; Lu LL; Gong W; Zhang AH
    Horm Metab Res; 2021 Nov; 53(11):730-737. PubMed ID: 34740274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Moriishi M; Kawanishi H; Fukagawa M
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():62-6. PubMed ID: 21595855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels.
    Eriguchi R; Umakoshi J; Miura S; Sato Y
    Clin Nephrol; 2009 Dec; 72(6):423-9. PubMed ID: 19954718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
    Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
    Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
    Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
    Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
    Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
    Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
    Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.
    Kanis JA; Johnell O; Black DM; Downs RW; Sarkar S; Fuerst T; Secrest RJ; Pavo I
    Bone; 2003 Sep; 33(3):293-300. PubMed ID: 13678769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
    Downs RW; Moffett AM; Ghosh A; Cox DA; Dowsett SA; Harper K
    Osteoporos Int; 2010 Jul; 21(7):1215-26. PubMed ID: 19798460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between baseline values of bone turnover markers and bone mineral density and their response to raloxifene treatment in Japanese postmenopausal women with osteoporosis.
    Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    Endocr J; 2008 Mar; 55(1):41-8. PubMed ID: 18187874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5.
    Haghverdi F; Farbodara T; Mortaji S; Soltani P; Saidi N
    Iran J Kidney Dis; 2014 Nov; 8(6):461-6. PubMed ID: 25362221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
    Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
    J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of raloxifene treatment in postmenopausal women with CKD.
    Ishani A; Blackwell T; Jamal SA; Cummings SR; Ensrud KE;
    J Am Soc Nephrol; 2008 Jul; 19(7):1430-8. PubMed ID: 18400939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.